Pharmana Wider View Vol.2 - Cardiovascular Disease

Pharmana Wider View Vol.2 – Cardiovascular Disease

Pharmana Wider View Vol.2 – Cardiovascular Disease https://manadvisory.com/wp-content/themes/movedo/images/empty/thumbnail.jpg 150 150 mana mana https://secure.gravatar.com/avatar/6cf6ef8dcdf39a9d8adec41bb1765d31?s=96&d=mm&r=g August 5, 2019 August 6, 2019

PHARMANA WIDER VIEW - August 2019 Vol2

Cardiovascular disease (CVD), or heart disease, is an umbrella term that includes all conditions affecting the heart.
By 2020, 50 percent of global health care expenditures – about $4 trillion – will be spent on three leading causes of death: cardiovascular diseases, cancer and respiratory diseases.
According to WHO report in 2010, the age standardized rates of CVD and diabetes-related deaths in Iran were 421 per 100,000 in men and 348 per 100,000 in women.

Read Pharmana Wider View: Vol2.Cardiovascular Disease to get insights

Topics in this newsletter:

In the Heart of Cardiovascular Disease
Suggested steps for MedTech in CVD
Evercore; Investment Banking Advisory
Iran National Innovation Fund
The Research and Technology Fund of Iran University of Science and Technology
Tehran and NYSE Stock Index
Mergers and Acquisitions (M&A) Term

Advanced in Science and Technology
Takeda – Shire Blockbuster Deal & Risks
Expanding Access to Low Cost, High-Quality Tertiary Care
Independence Against Sanctions by Innovation
American Depositary Share (ADS) Term
What is Respite Care?

PHARMANA WIDER VIEW - August 2019 Vol2

Download WIDER VIEW Vol.2 - August 2019

Special Partners